Okay, I think we'll get started. I'm Eric Joseph, Senior Biotech Analyst with J.P. Morgan. It's my pleasure to welcome and introduce our next presenting company, Mirati Therapeutics. Speaking on behalf of the company is CEO, David Meek. We will be doing Q&A in the room after the presentation. There'll be mics circulating around. For those who want to submit a question via the digital conference book, feel free to do so, and I'll work those in where appropriate. With that, David. Thank you, Eric, good morning, everybody, welcome to the Mirati Therapeutics conversation. I look forward to sharing with you a great update for Mirati. Before we begin, here's our forward-looking statement to talk about the risk to our business going forward. Mirati is very well-positioned to deliver best-in-class, first-in-class treatments and to drive remarkable shareholder growth. We are now a commercial-stage oncology company with a demonstrated ability to deliver innovative, potentially best-in-class and best treatments to treat patients with high unmet needs in cancer. There's three pillars I'm going to talk about today. The first is proven leadership in KRAS discovery and development. Mirati is a proven leader. When we look across the KRAS mutations, KRAS G12C, KRAS G12D, next gen KRAS, as well as, other KRAS programs that we have early in our discovery pipeline, there's nobody better, to look at this based on our expertise and experience. We have a scalable and synergistic lung cancer portfolio that we think is very important from discovery, development, all the way through to commercialization. We have a pretty specific focus on lung cancer, and we think we can leverage these synergies. Third, we have an innovative portfolio targeting areas of unmet need. We are relentlessly focused on delivering best-in-class and first-in-class targeted oncology therapies for patients. Finally, we're backed by a cash runway into 2025. We have 2+ years of cash. We're extremely disciplined and data-driven in how we deploy our capital, we understand how important it is to deploy our capital to the highest and to the investments that have the highest return for patients and overall for the business. We'll touch more upon this throughout the conversation. Let me begin first by talking about KRAZATI or adagrasib. KRAZATI was approved about a month ago. This was a significant milestone for patients as well as Mirati. KRAZATI was approved for patients that have non-small cell lung cancer who harbor the KRAS G12C mutation and who have had at least one prior line of therapy. Very exciting again for physicians, for patients, and also for Mirati. Let me talk about how we're going to establish KRAZATI as a second-line standard of care for patients with the KRAS G12C mutation and non-small cell lung cancer. There is a meaningful opportunity. There are 7,000+ second-line patients in the U.S. each and every year, so we think this is an opportunity that we can exploit to deliver a better therapy. The drivers of our commercial success are pretty clear, is we need to, and we will differentiate the best-in-class efficacy profile of KRAZATI, including the CNS penetration. We have a highly experienced team that is our commercial organization. They are lung cancer specialists. The average tenure in oncology is over 19 years with this organization. They know the community oncologists extremely well, and the community oncologists are the ones that treat the vast majority of patients with lung cancer. We have a unique distribution model as well as a customer engagement platform that we think will help accelerate our launch. Our launch priorities are threefold. We want to drive KRAZATI trial and adoption. This is by educating the oncologist around the efficacy profile of the overall response rates, the progression-free survival, and importantly, the overall survival data that we have. Then finally, the CNS penetration of KRAZATI. We will generate unrestricted and rapid access and affordable patient access for patients so they can immediately try KRAZATI as soon as possible. This work has been underway for more than a year, and we're very pleased with the first month so far regarding patient access. Finally, we want to expand the eligible second-line plus patient population. We have not yet fully penetrated the number of patients that should be tested and treated in the second-line plus with the KRAS G12C mutation. This is how we're going to establish KRAZATI as a second-line treatment of choice. The approval is just the beginning of a very long and successful journey that we have with KRAZATI, and it begins now. The profile is clinically meaningful, and this begins with the differentiated molecular profile that KRAZATI offers. We offer multiple paths to long-term value creation, as one can see in this chart, beginning with the approval in second line and many new indications and new tumor types along the way. KRAZATI can be both monotherapy as well as combination therapy, and we've got compelling evidence across multiple tumor types as well as multiple lines of therapy. We're combinable with checkpoint inhibitors. The data that we shared for the past six months has shown that adagrasib can be combined with checkpoint inhibitors. It is safe, and it is tolerable. We received breakthrough therapy designation at the end of last year for colorectal cancer in the 3rd line plus setting, along with a simultaneous publication in the New England Journal of Medicine. These are the value drivers that will build KRAZATI into a very big product for a very long time. Regarding the 1st-line setting for non-small cell lung cancer, we're going to take a data-driven approach to executing our 1st-line plan, and this is based on compelling data that we have for adagrasib plus pembrolizumab in combination. The experience today does provide confidence in our 1st-line strategy. There's a strong scientific rationale for improved durable outcomes relative to the 1st-line standard of care for this patient population. We do know adagrasib is combinable with a checkpoint inhibitor. While the efficacy is immature, it is maturing, and we do expect even better outcomes over time. Remember, the last data cut we had was from August of last year. Adagrasib combinability, we feel, provides a backbone foundation for many different combinations along many different tumor types as well as lines of therapy. How are we going to do this? We're going to take a data-driven development approach. There's a multi-pronged approach to the front-line setting. There's PhaseIII combination opportunities of adagrasib plus pembrolizumab. There's a PhaseII opportunity with adagrasib monotherapy and TPS less than 1%. We will begin exploratory combination studies of adagrasib plus chemotherapy plus a checkpoint inhibitor, and we're advancing this program we can invest very little money at this point in progressing the programs, and we will take a data-driven approach based on our ongoing PhaseII trial with KRYSTAL-7 as well as some other trials. We will take an informed approach before we deploy significant capital on this program. Again, a data-driven approach to the front-line setting, but we're real excited about what we've seen to date as well as the future in the front-line setting. Let me talk about our next KRAS program, and this is KRAS G12D, MRTX1133. Targeting KRAS G12D is very important. The patient population is about 2.5 times greater than the KRAS G12C patient population. KRAS G12D is a driver mutation. KRAS G12D and KRAS G12C are both highly potent oncogenes, and the KRAS G12D mutations are prevalent in high unmet need patient populations such as pancreatic cancer, colorectal cancer, as well as lung cancer. The chart on the right side shows the relative difference among the targeted oncology classes, you can see how big the KRAS G12D patient population is. We feel this is a big opportunity with significant unmet need. Last month, we submitted the IND for MRTX1133. The IND was submitted with a novel oral formulation to ensure robust clinical activity. We think 1133 has the potential to be the first-in-class KRAS G12D selective inhibitor. Let's talk a little bit more about our KRAS G12D program. It selectively and reversibly binds to and inhibits KRAS G12D in both the active and inactive states, demonstrates significant and selective regression of KRAS G12D mutation, but it's not KRAS wild type. We want to be clear about that. We have favorable properties, half-life greater than 50 hours, a low risk for off-target activity as well as drug interactions. With our novel formulation relative to traditional oral formulations, we have a 10 times greater bioavailability, and we expect near complete target inhibition over the full dosing interval with our KRAS G12D program. How are we going to advance our G12D program into the clinic? Our PhaseI will initiate in early 2023. We're able to leverage, and I talked about synergies earlier, we're able to leverage the experience that we have with adagrasib, similar team members, similar pathway to registration. We can leverage that group and rapidly advance KRAS G12D 1133 into the clinic for monotherapy as well as combination development. We'll have multiple expansion cohorts in the Phase I program in pancreatic, colorectal cancer, lung as well as other G12D patients. One piece of information I want to share with you regarding MRTX1133 is the marked tumor response in preclinical studies. This was data that was published last year. The durable maximal KRAS G12D pathway inhibition, it's linked to maximal tumor response. You can see that MRTX1133 demonstrated marked tumor response in pancreatic cancer models, which is on the right-hand side of the chart there. The human pharmacokinetic modeling provides and projects maximal target coverage following oral administration, and we think this is very important at a clinically achievable dose levels. We're moving rapidly with our 1133 program into the clinic. Let's talk about our next program, which is MRTX0902, which is also in the K-RAS family. It's a KRAS signaling modifier. MRTX0902 has the potential to improve efficacy in combination with KRAS inhibitors as well as other targeted therapies. It is a potential first-in-class SOS1 inhibitor, which is it's a critical regulator of KRAS and receptor TKI or tyrosine kinase such as EGFR signaling. It is a potent and selective small molecule that disrupts the KRAS and SOS1 interaction, shifting KRAS to its inactive state, which is important and represents a potential best-in-class SOS1 inhibitor. The other point is the potential to be highly synergistic in combination with KRAS G12C, such as adagrasib or KRAZATI, KRAS G12D, which is MRTX1133, and potentially other targeted therapies such as EGFR inhibitors too. Our PhaseI/II clinical program began a few months ago in the Q4 of 2022. Another opportunity for Mirati to bring forward best-in-class, first-in-class assets. Let's talk about the synergistic lung cancer portfolio. We have a robust and highly synergistic lung cancer portfolio, which we think is a meaningful and differentiated opportunity in lung cancer. When one looks at this chart on the right, you can see the four different assets all targeting non-small cell lung cancer. The commercial and operational synergies that we have in our portfolio, we think can drive significant value over time. We've got a highly experienced lung cancer organization, not just in commercial, but in discovery as well as drug development. When we think about commercial launches, and I'll get to one in a minute, when we think about commercial launches, it's really incremental and minimal incremental spend to commercialize other assets going forward for Mirati. That next asset that I want to talk about is sitravatinib, is a highly synergistic opportunity for Mirati. Sitravatinib had compelling PhaseII clinical trial results that provide confidence to us in the PhaseIII SAPPHIRE outcome. We've got the potential to establish sitravatinib plus nivolumab as a new standard of care after checkpoint inhibitor failure in non-small cell lung cancer. This lung cancer patient population is about 100,000 patients in the U.S. and Europe. 70,000 of those patients have the non-squamous histology. We had very encouraging data in our PhaseII program where the median overall survival was 14.9 months in second or third line patient population. Importantly, these patients had a prior clinical benefit based on prior checkpoint inhibitor therapy. This, we think, is a differentiator for us going forward. You can see the results of 56% and 32% of patients were alive at one and two years respectively. Our Phase III SAPPHIRE trial will read out in the Q2 of this year. The inclusion criteria of prior clinical benefit is a differentiator. We're confident in the outcome of this trial that we'll find out in a few months. We think the trial is different. We think the outcomes will be different with the sitravatinib plus nivolumab trial, the SAPPHIRE trial. Let's talk about our differentiated discovery and preclinical capabilities that we're extremely proud of that deliver sustained innovation for us over time. We have a highly productive discovery and preclinical organization that has created value for us and will create tremendous value going forward. For example, we've had four INDs in just the last four months. Some of these INDs I've already talked about. Our research organization has published 30 patents, with just a portfolio of projects of both preclinical as well as our clinical compounds. Highly productive organization. We see this as an opportunity to continue to discover and develop further programs that will complement our existing pipeline as well as new and innovative oncology targets. The next new oncology target to talk about that's come out of our discovery organization is our PRMT5 inhibitor, MRTX1719. This is a novel PRMT5 inhibitor selected for the MTAP-deleted cancers. MTAP deletion occurs in about 10% of all human cancers, including lung cancer, as I talked about earlier. Pancreatic mesothelioma is just a few examples. These patients have a poor prognosis. PRMT5 inhibitor MRTX1719 was internally discovered. It is an MTA-cooperative PRMT5 inhibitor, which we think offers a potential precision medicine for MTAP-deleted cancers. It leverages a synthetic, this is important, a synthetic MTA-cooperative, lethal approach and selectively targets PRMT5 and MTA complex in the MTAP-deleted cancer cells. This is designed to spare the normal cells as well to enhance the therapeutic index. If you think about the first generation PRMT5 inhibitors, there were some toxicity issues. We think we're able to get around that. Our broad therapeutic index allows full target coverage, which we think is important for maximal tumor regression. Our clinical development program, we've been in the clinic for about a year now at this point. We were granted fast track designation in Q3 of last year, and dose escalation is going very well, and we're real excited to talk about this program throughout 2023. Finally, I want to talk about organizational capabilities, capital deployment, and upcoming key catalysts we have. We have multiple pillars to drive long-term success and optimization in Mirati's differentiated portfolio and our capabilities. These pillars are four-fold: people, pipeline, partnering, and capital. Let me talk about people. I've talked about the highly experienced and expert team that we have at Mirati. We've got folks that are fantastic and world-class in discovery and development as we ramp up our commercial organization. They know targeted oncology extremely well, and this team, we're really proud to have this team at Mirati. Our pipeline is a broad pipeline of targeted oncology medicines that are first or best in class, and we are relentlessly focused on bringing forward more of these first in class, best in class, not just assets, but also new indications. Our partnering, we have been a significant partner in co-development, we will continue to explore other partnering opportunities to raise capital, to mitigate risk, and so on. Partnering is part of our DNA at Mirati. Finally, capital. I've got a full slide dedicated to capital, but we have two years of cash runway for capital, and let me move to that slide now. We're very disciplined in how we deploy our capital. We understand how important it is to deploy our capital to the programs that are going to deliver the highest return and also in a very data-driven manner. We're going to remain disciplined on our capital deployment. As of the end of 2022, we have about $1.1 billion, and we have cash runway into 2025. Revenue from KRAZATI begins, as we talked about earlier with the launch, this will offset some of the burn in 2023. Our 2023 operating burn is going to be similar to what it was in 2022, which is about $140 to 150 per quarter. That's where we are on the cash side. We will focus our investments only on those indications or programs that have the highest opportunity for return, and that's how we'll deploy our capital. We will also we'll shut down or stop or deprioritize other programs that do not have the data to be first or best in class. Those programs will not be invested in the future. We have many upcoming catalysts and data readouts. Again, we understand how important it is to deploy our capital, and we're going to do so in a very disciplined and data-driven manner. Let's talk about some of the catalysts. We've got multiple catalysts throughout the year. I'm not going to go through each one of these catalysts. I'm sure we'll talk about them. You can see we have catalysts for adagrasib, MRTX1133, MRTX0902, Sitravatinib, and MRTX1719 across the board. These are our key catalysts that we have for Mirati. I just end by thanking you very much for your attention and thanking you very much for your interest in Mirati. We've got a very exciting year ahead after a very successful year last year, thank you for your support. We're now going to take questions, right, Eric? Yes, we're going to move straight to questions. Let's have the Mirati team come up. Is that okay? We're going to have a couple folks join. Absolutely. A A couple members come on up. Yeah, absolutely. Just do a quick intro of the team. We have James Christensen, our Chief Scientific Officer, Laurie Stelzer, our CFO, Alan Sandler, our Chief Medical Officer, and Ben Hickey, our Chief Commercial Officer. They've joined me on stage. Maybe let me just start off with... Oh, thank you. If I could just start out with questions. Starting with the KRAZATI launch. Obviously, it's early days since the approval, but I'm just curious to get a sense of the initial physician reaction to the label. Then also, as we think about the launch, sort of what's the... Is there a focal logjam, I guess, that you'd look to overcome in terms of just facilitating as rapid access to the drug as possible, whether it's increasing the rate of sorry, 12C testing, payer coverage, and the like? Yeah. Thanks, Eric. Ben will go into the details as a reminder, we were approved just less than a month ago. We were able to launch rapidly. We think it's very important to get drug to patients and make it available to patients as soon as possible. The team did a great job of that, we were able to deliver within a few days. We're now a month into it. The early days are very encouraging, Ben will tackle that. Sure. We started very quickly. We got product in the channel within days. We've been very focused on operations, so ensuring that we had product in the channel, ensuring that all the order sets, whether it be in the community or at the academic centers, are all in place so they can actually order product. We're at 98% from an order set standpoint. We've initiated access discussions both on the payer side as well as presented a community contract, which is being communicated out to all of community oncology, where about 75% of lung cancer is treated. We educated and had our salesforce out, our access team out, and our medical team out within 24 hours of the approval. Off to a quick start. Operationally, I would say that the physician feedback so far has been very positive. The label was largely as expected, no real surprises there. They're excited to ensure that they utilize the product and use the tablet format, which we launched with. I think from what we're going to be looking at is a couple of things. One, we'll be looking at new-to-brand share as a key metric and to measure our competitiveness. As you'd mentioned in the question there around growing the market, we still think there's a pretty big opportunity to grow the market around both biomarker testing as well as making second-line patients available in the EMR system for the physician. All so far so good. Super excited. We've a dedicated team out there that couldn't be more excited and energized to bring KRAZATI to patients and physicians. Maybe just thinking about the confirmatory study as well in this setting, KRYSTAL-12. You recently updated the protocol there to expand the size of the study. I just wonder whether sort of there's any potential competition for patient impact as a result of upsizing the size of that trial? Also, sort of how should we be thinking about the survival benefit that you're now sort of adequately powered to show in terms of PFS and OS? Let me just start off and then pass it over to Alan. The trial you mentioned about competition, this trial will be largely conducted outside the U.S. We will not be competing for commercial patients in the U.S. Again, the majority of the patients will come from ex-U.S. Alan can answer the other part of the question, Eric. Yeah. Great. Thanks. A couple important points about the study and the reason for expanding it to approximately 700 patients. We have a co-primary now with PFS and OS. We have the opportunity to read out early with that PFS that will be coming out. PS-PFS endpoint middle perhaps of next year. This allows us to have two attempts to win with this study with PFS and OS, and also very importantly, have the first opportunity to show a survival advantage in this G12C population. This is something we're extremely excited about and looking forward to that. Just a reminder on that one of the catalysts we put on the slide is for the dual endpoint of PFS and OS, we'll have a PFS and we should see PFS in first half of 2024 for the KRYSTAL-12 trial. perhaps partnering factors into this, I guess how should we be thinking about the European opportunity with KRAZATI right now and sort of the timing in which you might engage the market, whether it's partnered, whether it's independently and to the extent the KRYSTAL-12 readout might impact that decision? Sure. Yeah. First of all, KRYSTAL-12 will play an impact in that. Just to step back a second. The marketing authorization application for KRAZATI or adagrasib is sitting in front of the EMA right now. We expect approval in Q3 of 2023. As reimbursement timelines take a while, there's really no revenue until 2024. We have a little time. We're exploring partner opportunities. We're going alone in the U.S. for sure. We will be open to exploring opportunities in the U.S. Physicians also have a lot of, and increasingly so, firsthand experience with adagrasib. I mentioned KRYSTAL-12. A lot of those patients will come from Europe or other clinical trials. Physicians are gaining exposure, so there's quite a bit of awareness, and also clinical use of adagrasib ex-U.S. already. Stay tuned for later this year. Mm-hmm. We'll assess this. Perhaps. I would say too, it is an opportunity for capital and risk mitigation, so there are clearly some pros to that approach if we take that approach. Okay. sorry. Here. The different compound for the non-small cell lung cancer would be you'll work them as a portfolio, in a portfolio approach. I mean, would they be complementary or they would be eating from each other? How would? That's a great question. It, for the most part, complementary. when we think of Sitravatinib plus nivolumab, it's a different patient population. The KRAS G12C patient population is different. We really don't see cannibalization so much of our own portfolio. KRAS G12C patients are different than G12D patients, so more complementary and synergistic of the overall portfolio we have. Our SOS1 program would be, say, as a combination with adagrasib or with MRTX1133 to improve efficacy outcomes. Okay. If that helps. Anything else, guys? Okay. Good morning. Beyond Europe, do you have an idea to other markets, to open other markets like Latin America and so on? Other market, we do have a partnership with adagrasib or KRAZATI. We have a partnership today with Zai, they will handle China. They're also helping us. They're very constructive in helping us with our clinical trials. They'll enroll quite a few patients in our clinical trials. With Sitravatinib, we have a partnership with BeiGene, also China and some other territories. Regarding Latin America and other markets like that, we have not yet made a decision on what we're going to do there. Anybody else? Maybe just add that with the in Japan, CRC is a pretty big opportunity. We've been considering how we look at bridging studies and enroll patients in studies there to then expedite a path to Japan. We do fundamentally believe our drug should be available to all patients around the world, and we're going to do what we can to make that happen, as well as the revenue opportunity that presents itself. How about South Korea? Same. Uh- We'll do the same. whether we do a partner or do it alone. We're looking at all these markets. And I'd like- That's an important market, as you know. Uh. Yes. I'd like to ask about any update to compare efficacy and safety of KRAZATI compared to a rival drug like Amgen. Could you tell us that? You mean like a head-to-head trial? Yes. Sure. You want to tackle that? Yeah. Like I said, there's no plans currently to do anything head to head at this point. There's no upcoming data. Yeah. Our real plan is to show improvement with adagrasib as monotherapy or combination therapy relative to current standard of care. There will be cross-trial comparisons. I'll mention that, 'cause I just to be sure that I capture your question appropriately. There's the potential with all the caveats in place, to look at the data when it comes out. In particular, K-12 was one where we're doing a randomized study against a similar control arm and with an opportunity to show overall survival for the first time in that particular setting. That, I think is a key opportunity. I'm sorry, just wait for the microphone. Sorry, a little hard to hear. Are you guys seeing any resistance in the patients that are already treated in these trials to the KRAS resistance? Jamie, you want to tackle that? Resistance to, KRAZATI, KRAS G12C inhibitors. Sure, yeah. I think the first wave, has published in The New England Journal of Medicine. This really indicates that there are multiple mechanisms by which patients can become resistant to adagrasib. That includes mutations of KRAS, either in, at the G12 codon or at other sites in the switch-II pocket, and includes upstream receptor tyrosine kinases, and includes downstream signaling modifiers for KRAS. I would just add that, we also do have an extensive effort ongoing in the program to look at different combinations of adagrasib with other drugs, and would say that some of the other drugs and targeted therapies that we're combining adagrasib with are really intended or anticipated to block some of these resistance mechanisms, and then overall enhance the efficacy profile of adagrasib. Well, yes. Just wanted to ask, quickly on the liver tox. Is there a chance that you can do prophylactic steroid use? Is that something you're considering? How do you currently deal with that? want to take it, Jamie? Sure. Yeah, I would say we really don't see liver tox as a limitation for either monotherapy or combination therapy. The vast majority of liver function test enzyme elevations we see in the first 30 days or first 2 cycles. These generally tend to resolve on their own or with dose reduction or dose interruption. This has not been a limiting factor for the program, including the pembrolizumab combination to date. Can I just ask a question about the G, the G12D-MRTX1133, which is really relative to adagrasib? Is there anything that you can say about sort of the relative therapeutic window as that, yeah, that you expect as that program moves into patients? Then also, I guess given the fact that there's really a dearth of competition out there for you guys, how do you expect the PhaseI to accrue? There's the competition also a relatively larger addressable population given the prevalence of the mutation. Sure. Yep. First, I guess to address your last question on competition, I'd say one key thing is that there are 3.5 times more patients for KRAS G12D versus KRAS G12C. Second point is this field isn't competitive, as competitive currently as it is for KRAS G12C for patients. Finally, there are really high unmet medical need populations like pancreatic ductal adenocarcinoma, where there are really no effective treatments, including standard of care. We would expect enrollment to go reasonably fast. What was your first question really? Therapeutic window. Sure. Yeah, I mean, we have looked at KRAS G12D inhibitor. It has about a 1,000-fold selectivity for KRAS G12D versus wild type, so we do not expect any toxicities that could potentially be mediated by targeting wild type to emerge from the clinical trial for that reason. Number two is we've looked at broad profiling of ion channels, other potential off targets or otherwise. The 1133 molecule is quite clean, and we haven't identified any additional targets. Just as a reminder, this is a non-covalent inhibitor as well. Finally, we have gone through regulatory toxicology studies to support the IND filing, which happened last year. Would say that there has been a broad therapeutic index observed in preclinical studies. We would anticipate the same in humans, and we're quite excited about moving that program forward into patients to see how it does. Yeah, Eric, I'll just add a little bit more you talked about the synergy during my presentation. When we think about the sites and so on, the investigators, these are very similar to what we had in the G12C clinical development program. We've got this all established, so we're not starting from scratch. This is why we think we can move with pretty good velocity through the development cycle of 1133. There are obviously some rational combinations that you might look to pursue, right? Absolutely. whether it's EGFR, PD-1, how early on in the development cycle will you have an opportunity to look at that? Mm-hmm. yeah again we're pretty compelled by this program. As soon as we find a recommended phase two dose, which we think we could do reasonably early in the program of course, we're going to have to see how the trial shakes out, but we have a reasonably a starting dose within the therapeutic range. We can escalate fairly quickly. As soon as we're confident in a recommended phase two dose, we would be looking at combinations such as cetuximab, SOS1 inhibitor, and really an indication-driven combination strategy as well, whether it's in pancreatic cancer, lung or colon, looking at complementary combination strategies. We have time for one more quick question, if possible. Yeah. Do you have plans to study it in the first line treatment or, because, today it's in the second line? adagrasib or KRAZATI? KRAZATI. We do have plans to study in the first line setting for non-small cell lung cancer, yes. We do have that plan. There's a multipronged approach to going to the front line setting as monotherapy as well as multiple combination programs. We see tremendous value opportunity in the front line setting. Just a reminder we're the only KRAS G12C inhibitor that can be combined with a checkpoint inhibitor to, at this time. It would be the... Jamie, you want to tackle it with the G12C patients? Yeah. We will be retrospectively looking at all either genetic or PD-L1 status biomarkers as part of our trial and determining whether the drug has any greater than proportional activity in any given segment that could support a niche development strategy. Right now, our plan is to look across all TPS strata and all mutations for the combination, and our data supports that to date. Okay. Well, we'll have to wrap it there for time. Thanks very much, Mirati team, for your time this morning. Appreciate it.